Patent focus on cancer chemotherapeutics. IV angiogenesis agents: April 2001 - August 2001

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 12, 2001, Pages 1919-1945

  Connell, R D ^a   Beebe, J S ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

v 3; v 5; Angiogenesis; Angiopoietin; Angiostatin; Cancer; Catechin; Endostatin; Fibroblast growth factor (FGF); Flavinoids; Flt; Gelatinase; Growth factor inhibitors; HGF; Hydroxamate; Integrin antagonists; KDR; Krigle; Marimastat; Matrix metalloprotease (MMP); Metastasis; Neovascularisation; Patent; PDGF; PTK 787; Receptor tyrosine kinases; RGD; secreted proteins; Stromelysin; SU 5416; Tek; Tie2; TIMP; TKI; TNP 470; Tumour; uPAR; Urokinase; Vascular targeting; Vasostatin; VEGF; Vitronectin

Indexed keywords

2 METHOXYESTRADIOL; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; AG 2033; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAPECITABINE; CARMOFUR; DOXIFLURIDINE; EPIGALLOCATECHIN GALLATE; FLOXURIDINE; FLUOROURACIL; GROWTH FACTOR; HEPARIN DERIVATIVE; IMATINIB; INTEGRIN; MATRIX METALLOPROTEINASE INHIBITOR; N [[5 [2 (2 AMINO 4,6,7,8 TETRAHYDRO 4 OXO 1H PYRIMIDO[5,4 B][1,4]THIAZIN 6 YL)ETHYL] 2 THIENYL]CARBONYL]GLUTAMIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; REAGENT; TEGAFUR; TYRPHOSTIN; UFT; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BLOOD VESSEL; CANCER CHEMOTHERAPY; CANCER GROWTH; CAPILLARY; CLINICAL STUDY; CONTROLLED STUDY; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SELECTIVITY; HUMAN; HUMAN CELL; METASTASIS; NONHUMAN; PATENT; PUBLICATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0035207826     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.12.1919     Document Type: Article

References (57)

1. Postnatal vasculogenesis
2. Tumor angiogenesis as a therapeutic target
3. Anti-angiogenic strategies and agents in clinical trials
4. Clinical trial designs for cytostatic agents: Are new approaches needed?
5. Cancer Chemotherapeutics-Angiogenesis Agents: October 1999 - March 2000
6. Patent focus on cancer chemotherapeutics. II angiogenesis agents: April 2000 - September 2000
7. Patent focus on cancer chemotherapeutics. III Angiogenesis agents: October 2000 - March 2001
8. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
9. Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis
10. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis
11. Matrix metalloproteinases: They're not just for matrix anymore!
12. Matrix metalloproteinases: Pro- and anti-angiogenic activities
13. The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis
14. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors
15. Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines
16. Heterocycle-based MMP inhibitors with P2 substituents
17. Potent and Selective Carboxylic Acid-Based Inhibitors of Matrix Metalloproteinases
18. Novel 5,5-disubstituted-pyrimidine-2,4,6-triones as selective MMP inhibitors
19. X-ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysin
20. A highly efficient method for the preparation of phosphinic pseudodipeptidic blocks suitably protected for solid-phase peptide synthesis
21. Phosphinic peptide inhibitors of macrophage metalloelastase (MMP-12). Selectivity and mechanism of binding
22. Selective, orally active MMP inhibitors with an aryl backbone
23. Synthesis and activity of selective MMP inhibitors with an aryl backbone
24. α-Amino-β-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1
25. α-Alkyl-α-amino-β-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1
26. Design and Synthesis of Cyclic Inhibitors of Matrix Metalloproteinases and TNF-Production
27. Design, Synthesis, and Structure-Activity Relationships of Macrocyclic Hydroxamic Acids That Inhibit Tumor Necrosis Factor Release in vitro and in vivo
28. Nonpeptide vitronectin antagonists labeled with Tc99m for imaging tumors
29. Development of inhibitors for protein tyrosine kinases
30. Protein tyrosine kinase inhibitors as therapeutic agents
31. Protein kinase inhibitors: Emerging pharmacophores 1997-2000
32. Monoclonal antibody strategies to block angiogenesis
33. Tek/Tie2 signaling: New and old partners
34. Tie receptors: New modulators of angiogenic and lymphangiogenic responses
35. Angiopoietin and Tie signaling pathways in vascular development
36. Selective tyrosine kinase inhibitors
37. Selective platelet-derived growth factor receptor kinase blockers reverse sistransformation
38. VEGF receptor signaling in tumor angiogenesis
39. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors
40. Efficacy of the anti-angiogenic approach to solid tumors
41. Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective alpha v beta 3 integrin antagonists
42. 3 antagonists based on a central thiophene scaffold
43. The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer
44. The role of the plasminogen activation system in angiogenesis and metastasis
45. Development of Serine Protease Inhibitors Displaying a Multicentered Short (< 2.3 Å) Hydrogen Bond Binding Mode: Inhibitors of Urokinase-Type Plasminogen Activator and Factor Xa
46. Angiostatin and endostatin: Endogenous inhibitors of tumor growth
47. Endogenous angiogenesis inhibitors and their therapeutic implications
48. Anti-inflammatory and antitumor efects of flavonoids and flavonoids
49. Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate
50. New drug leaves cancer cells gasping for air
51. Anticancer prodrugs for application in monotherapy: Targeting hypoxia, tumor-associated enzymes, and receptors
52. New Hope for matrix metalloproteinase inhibitors in cancer therapy
53. In vitro models of vasculogenesis and angiogenesis
54. Angiogenesis assays: Problems and pitfalls
55. US Supreme Court Decision could compromise biotech patents